Drug profile · INN
upadacitinib
RINVOQ
upadacitinib (RINVOQ) is a tyrosine-protein kinase tyk2 inhibitor. Associated with AbbVie. Route of administration: oral. Current US regulatory status: approved.
Drug details — upadacitinib
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L04)
- Route
- ORAL
- Patents
- 3
- Programs
- 24
- Data quality
- 0.84
Quick answer
upadacitinib (RINVOQ) is a tyrosine-protein kinase tyk2 inhibitor. Associated with AbbVie. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Tyrosine-protein kinase TYK2 inhibitor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| NMPA | clinical trials | — |
Recent coverage
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is upadacitinib?
upadacitinib (RINVOQ) is a tyrosine-protein kinase tyk2 inhibitor. Associated with AbbVie. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for upadacitinib?
RINVOQ is a marketed brand name for upadacitinib. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of upadacitinib?
upadacitinib has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.